Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating activities
Net loss	$ (109,157,000)	$ (87,547,000)
Adjustments to reconcile net loss to cash used in operating activities:
Stock-based compensation expense	43,609,000	28,415,000
Depreciation and amortization	4,571,000	2,569,000
Noncash rent expense	(186,000)	0
Amortization of debt issuance costs, discounts and premiums	0	258,000
Change in fair value of warrant liabilities	(30,968,000)	6,952,000
Change in fair value of earn-out liability	(26,870,000)	1,869,000
Change in fair value of earn-out liability	167,000	0
Amortization of premium (accretion of discount) on available-for-sale securities, net	(977,000)	380,000
Provision for excess and obsolete inventory	490,000	703,000
Provision for (recovery of) doubtful accounts	150,000	(8,000)
Cloud computing arrangement expenditures	(11,127,000)	(3,412,000)
Loss on extinguishment of debt, net	0	4,323,000
Loss on disposal of property and equipment	2,411,000	0
Paid-in-kind interest	0	165,000
Income tax benefit	(806,000)	0
Other	15,000	19,000
Changes in operating assets and liabilities:
Accounts receivable	(9,366,000)	383,000
Inventory	(3,732,000)	(2,957,000)
Deferred costs of services	(875,000)	988,000
Prepaid expenses and other current assets	133,000	(3,909,000)
Other long-term assets	(106,000)	0
Accounts payable	2,340,000	6,460,000
Deferred revenue	29,730,000	208,000
Accrued and other liabilities	9,885,000	4,509,000
Payment of paid-in-kind interest on extinguishment of debt	0	(752,000)
Net cash used in operating activities	(100,669,000)	(40,384,000)
Investing activities
Palamedrix acquisition, net of cash acquired of $2,521	(13,256,000)	0
Purchases of property and equipment, net of proceeds from sales	(5,215,000)	(3,307,000)
Purchases of available-for-sale securities	(186,687,000)	(279,918,000)
Proceeds from maturities of available-for-sale securities	287,700,000	101,206,000
Net cash provided by (used in) investing activities	82,542,000	(182,019,000)
Financing activities
Proceeds from exercise of stock options and employee stock purchase plan	5,185,000	3,947,000
Repayment of long-term debt	0	(36,512,000)
Proceeds from PIPE Investment, net of transaction costs	0	357,198,000
Proceeds from SPAC Merger, net of transaction costs	0	172,858,000
Net cash provided by financing activities	5,185,000	497,491,000
Effect of exchange rates on cash, cash equivalents and restricted cash	(43,000)	(14,000)
Net (decrease) increase in cash, cash equivalents and restricted cash	(12,985,000)	275,074,000
Cash, cash equivalents and restricted cash at beginning of period	440,268,000	165,194,000
Cash, cash equivalents and restricted cash at end of period	427,283,000	440,268,000
Supplemental cash flow information:
Cash paid for interest	0	1,627,000
Supplemental disclosure of non-cash investing and financing activities:
Purchase of property and equipment included in accounts payable	395,000	615,000
Operating lease assets obtained in exchange for lease obligations	5,318,000
Issuance of Common Stock upon SPAC Merger	11,832,000	151,082,000
Contingent consideration payable for Palamedrix Acquisition	1,448,000	0
Surrender of shares in cashless exercise	0	56,000
Issuance of Common Stock for services	50,000	1,334,000
Forgiveness of Paycheck Protection Program loan and accrued interest	0	3,561,000
Issuance of Common Stock for conversion of convertible debt	0	4,631,000
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	421,830,000	439,488,000
Restricted cash included in prepaid expenses and other current assets	4,658,000	0
Restricted cash included in other long-term assets	795,000	780,000
Total cash, cash equivalents and restricted cash at end of period	$ 427,283,000	$ 440,268,000